A Brussels-based drugmaker recently became the seventh manufacturer to announce an expansion of its 340B claims data requirements to in-house pharmacy use, while a Chicago-based pharmaceutical giant updated its contract pharmacy restrictions to exempt Washington state covered entities.
UCB informed providers in a May 8 notice posted on the website for industry vendor 340B ESP that, beginning June 1, it will require all covered entity types to provide claims data for 340B pharmacy dispenses and medical claims from both in-house and contract pharmacy locations within 45 days of dispense.
UCB is the latest manufacturer to significantly expand its claims data requirements from contract pharmacy dispenses to all 340B purchases in recent months.
Meanwhile, AbbVie updated its 340B contract pharmacy policy to exempt Washington state covered entities as of June 10—the day that state’s contract pharmacy access law takes effect, according to a May 5 notice posted on 340B ESP.
The Chicago-based drugmaker also added Louisiana to the list of states subject to its exemptions, but removed North Dakota following legal actions affecting those state’s contract pharmacy access laws.
Claims Data Context
340B providers have strongly opposed in-house claims data policies, arguing they violate the 340B statute because the cost to comply would effectively drive the price of 340B drugs above their statutory ceiling price. Multiple national provider associations have also urged the Health Resources and Services Administration to take enforcement action, though the agency has yet to take a public position on these new policies.
Manufacturers, however, have argued that their policies would improve 340B program transparency and prevent duplicate discounts and drug diversion.
Beyond UCB, drugmakers Biogen, Bristol Myers Squibb, Eli Lilly, Novo Nordisk and AstraZeneca have each announced in-house claims data collection policies in 2026. Exelixis—a smaller, California-based specialty drug manufacturer—was the first manufacturer to require claims data at in-house pharmacies in a policy that took effect in October 2025.
340B Report has launched a new tracker to keep subscribers updated on manufacturer policies requiring 340B providers to submit 340B claims data on in-house pharmacy utilization.
UCB’s Policy
UCB said the new claims data requirements will apply to all covered entity types for pharmacy dispenses and medical claims “from both in-house pharmacy locations and contract pharmacy locations.” That includes grantee covered entities that were not previously required to submit claims data. The drugmaker added that the requirement “applies to UCB’s entire portfolio of products.” Covered entities must submit the data via 340B ESP within 45 days of a product’s dispense or they could risk losing access to 340B pricing.
UCB noted that “this policy is only effective where permitted by applicable state law.” The drugmaker did not list the states specifically exempted from its restrictions in its notice, like other drugmakers have done when announcing similar policies.
A UCB spokesperson told 340B Report that “as reflected in our materials, certain states have enacted legislation that affects the application of our contract pharmacy policy and associated claims data requirements.” They include: Arkansas, West Virginia, Kansas, Maryland, Mississippi, Missouri, Louisiana, Nebraska, Utah, South Dakota, Hawaii, New Mexico, Rhode Island, Vermont, Colorado, North Dakota and Oklahoma.
“In these states, UCB is applying its policy in a manner consistent with applicable state laws,” the spokesperson added. “We will continue to monitor legislative developments and adjust our approach as needed to remain compliant while supporting the intent of the 340B program.”
UCB said in its notice that “if applicable, states will be exempted from this policy according to the state exemption notifications provided outside this policy.” “Existing state carve-out exemptions will be unaffected by this policy change unless separately notified by UCB,” it added.
UCB previously exempted Arkansas and West Virginia covered entities from its 340B contract pharmacy restrictions.
AbbVie’s Policy
AbbVie announced it will add Washington to the list of states exempt from its 340B contract pharmacy restrictions as of June 10. Washington’s law, which prohibits drugmakers from restricting 340B discounted drug delivery to contract pharmacies and conditioning 340B access on claims data submission not required under federal law, takes effect June 10.
The drugmaker further included Louisiana—one of the first states to pass a contract pharmacy access law—on its list of exempted states in its May 5 notice. AbbVie noted that Louisiana covered entities “may access 340B pricing at an unlimited number of contract pharmacies” if they submit “limited” claims data via 340B ESP for each of their contract pharmacy arrangements within 45 days of the dispense date.
The move came shortly after Louisiana Attorney General Liz Murrill (R) told a national legal news service in late April that her office was preparing enforcement actions against multiple drug manufacturers over alleged violations of the state’s 340B contract pharmacy access law.
Louisiana in February secured a major federal appellate court victory defending the law against three manufacturer lawsuits.
AbbVie previously exempted Arkansas, Colorado, Hawaii, Maine, Maryland, Mississippi, Missouri, Nebraska, New Mexico, North Dakota Rhode Island, South Dakota, Tennessee and Vermont from its contract pharmacy restrictions.
The drugmaker, however, removed North Dakota from its list of exempted states in the May 5 notice.
A North Dakota federal judge on April 27 struck down the state’s contract pharmacy access law (H.B. 1473), siding with AbbVie, AstraZeneca and the drug industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA) which had challenged the statute.
Editor’s Note: This story was updated after publication to include UCB’s comment on state exemptions.
